⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288786 | 1.00 | — | — | |
| SCHEMBL1476244 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL17223559 | 0.98 | FDPS (0.43) | — | |
| Hydrochloric Acid SCHEMBL2035544 | 0.98 | FDPS (0.43) | — | |
| Bromide SCHEMBL9376271 | 0.98 | FDPS (0.43) | — | |
| Hydrochloric Acid SCHEMBL4060601 | 0.98 | FDPS (0.43) | — | |
| Bromide SCHEMBL9376277 | 0.98 | FDPS (0.43) | — | |
| Hydrochloric Acid SCHEMBL643019 | 0.98 | FDPS (0.43) | — | |
| Hydrochloric Acid SCHEMBL22800513 | 0.96 | FDPS (0.42) | — | |
| SCHEMBL644279 | 0.93 | FDPS (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250277012-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-09-04 | — | — | US | claimed |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | US | claimed |
| US-20240209053-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | claimed |
| EP-4355763-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS | Protagonist Therapeutics, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| CN-117813313-A | Binding hepcidin mimetics | 领导医疗有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-117730089-A | Binding hepcidin mimetics | 领导医疗有限公司 | 2024-03-19 | — | — | CN | claimed |
| US-20240066131-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | claimed |
| EP-4314014-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| EP-4314017-A1 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| US-20240018189-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | claimed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | claimed |
| US-9512139-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2016-12-06 | — | — | US | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | claimed |
| EP-2499148-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2012-09-19 | — | — | EP | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |